Physician

Barry Jay Mark, M.D.

According to 2025 Medicare claims, Barry Mark, M.D. (NPI: 1073527479) practices allergy/immunology in the Miami-Miami Beach-Kendall, FL market, with the plurality of this provider's patient population coming from Miami-Dade, FL. This provider's primary affiliated billing organization is ALLERGY & ASTHMA ASSOCIATES OF SOUTH FLORIDA PA (NPI: 1093779696; TIN: 591632544) and primary practice location at 33180-1250.

Mark's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 121 traditional Medicare patients, billed 6,434 HCPCS/CPT codes, and received $155,581 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 632 prescription claims across 126 beneficiaries totaling $224,531 in drug costs, led by Xolair (Omalizumab). DME data shows 59 claims. Open Payments data shows 59 records totaling $1,945. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $88,754 to $224,531. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	141	6,369	$98,945
2016	126	8,490	$162,194
2017	126	7,942	$172,104
2018	188	10,047	$231,026
2019	201	8,168	$178,208
2020	135	6,419	$159,530
2021	146	6,965	$162,534
2022	120	7,173	$179,956
2023	132	6,849	$158,883
2024	121	6,434	$155,581

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	148	661	$88,754
2016	132	520	$127,488
2017	119	553	$139,440
2018	92	447	$85,960
2019	129	574	$176,486
2020	128	573	$225,051
2021	117	486	$89,369
2022	108	557	$223,513
2023	111	523	$183,700
2024	126	632	$224,531

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	79	$72,067
2021	N/R	87	$88,078
2022	N/R	12	$36,892
2023	N/R	N/R	N/R
2024	N/R	59	$50,033

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	62	109	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	30	59	$67
94010	Test to measure expiratory airflow and volume	47	88	$20
95165	Professional service for preparation and provision of 1 or more antigens	34	1,453	$11
95117	Professional service for multiple injections of allergen	58	235	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xolair	Omalizumab	51	1,232	$109,093
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	27	990	$21,057
Breo Ellipta	Fluticasone/Vilanterol	25	870	$11,842
Symbicort	Budesonide/Formoterol Fumarate	43	1,470	$10,582
Dulera	Mometasone/Formoterol	13	569	$6,968

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	13	$47,929
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	23	$1,764
K0552	Supplies for external non-insulin drug infusion pump, syringe type cartridge, sterile, each	N	N/R	23	$339

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	59	$1,945	Amneal Pharmaceuticals LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Barry Jay Mark, M.D.?

Tedicare shows public-source Medicare data for Barry Jay Mark, M.D. (NPI 1073527479), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Barry Jay Mark, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Barry Jay Mark, M.D.?

Barry Jay Mark, M.D. is linked to ALLERGY & ASTHMA ASSOCIATES OF SOUTH FLORIDA PA (billing NPI 1093779696) in the available physician profile data.

Does Barry Jay Mark, M.D. have Open Payments data?

Barry Jay Mark, M.D. has 59 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.